TAP Pharmaceuticals, Deerfield, Ill., tapped Bates USA, New York, to serve as the first agency for its Prevacid direct-to-consumer account. The account reportedly is worth $40 million to $60 million, though a company spokeswoman declined to confirm that range. Prevacid is a prescription drug for ulcers and heartburn, and was the No. 2 seller last year in a market led by AstraZeneca's Prilosec, according to IMS Health. The review reportedly also included Chicago agencies Leo Burnett
USA and Cramer-Krasselt
Copyright September 1999, Crain Communications Inc.